212 related articles for article (PubMed ID: 36800423)
1. DUX4 double whammy: The transcription factor that causes a rare muscular dystrophy also kills the precursors of the human nose.
Inoue K; Bostan H; Browne MR; Bevis OF; Bortner CD; Moore SA; Stence AA; Martin NP; Chen SH; Burkholder AB; Li JL; Shaw ND
Sci Adv; 2023 Feb; 9(7):eabq7744. PubMed ID: 36800423
[No Abstract] [Full Text] [Related]
2. Increased DUX4 expression during muscle differentiation correlates with decreased SMCHD1 protein levels at D4Z4.
Balog J; Thijssen PE; Shadle S; Straasheijm KR; van der Vliet PJ; Krom YD; van den Boogaard ML; de Jong A; F Lemmers RJ; Tawil R; Tapscott SJ; van der Maarel SM
Epigenetics; 2015; 10(12):1133-42. PubMed ID: 26575099
[TBL] [Abstract][Full Text] [Related]
3. Cross-sectional Neuromuscular Phenotyping Study of Patients With Arhinia With
Mohassel P; Chang N; Inoue K; Delaney A; Hu Y; Donkervoort S; Saade D; Billioux BJ; Meader B; Volochayev R; Konersman CG; Kaindl AM; Cho CH; Russell B; Rodriguez A; Foster KW; Foley AR; Moore SA; Jones PL; Bonnemann CG; Jones T; Shaw ND
Neurology; 2022 Mar; 98(13):e1384-e1396. PubMed ID: 35121673
[TBL] [Abstract][Full Text] [Related]
4. SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain.
Lemmers RJLF; van der Stoep N; Vliet PJV; Moore SA; San Leon Granado D; Johnson K; Topf A; Straub V; Evangelista T; Mozaffar T; Kimonis V; Shaw ND; Selvatici R; Ferlini A; Voermans N; van Engelen B; Sacconi S; Tawil R; Lamers M; van der Maarel SM
J Med Genet; 2019 Oct; 56(10):693-700. PubMed ID: 31243061
[TBL] [Abstract][Full Text] [Related]
5. A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4.
Sasaki-Honda M; Jonouchi T; Arai M; Hotta A; Mitsuhashi S; Nishino I; Matsuda R; Sakurai H
Hum Mol Genet; 2018 Dec; 27(23):4024-4035. PubMed ID: 30107443
[TBL] [Abstract][Full Text] [Related]
6. A proteomics study identifying interactors of the FSHD2 gene product SMCHD1 reveals RUVBL1-dependent DUX4 repression.
Goossens R; Tihaya MS; van den Heuvel A; Tabot-Ndip K; Willemsen IM; Tapscott SJ; González-Prieto R; Chang JG; Vertegaal ACO; Balog J; van der Maarel SM
Sci Rep; 2021 Dec; 11(1):23642. PubMed ID: 34880314
[TBL] [Abstract][Full Text] [Related]
7. Small noncoding RNAs in FSHD2 muscle cells reveal both DUX4- and SMCHD1-specific signatures.
Lim JW; Wong CJ; Yao Z; Tawil R; van der Maarel SM; Miller DG; Tapscott SJ; Filippova GN
Hum Mol Genet; 2018 Aug; 27(15):2644-2657. PubMed ID: 29741619
[TBL] [Abstract][Full Text] [Related]
8. Smchd1 haploinsufficiency exacerbates the phenotype of a transgenic FSHD1 mouse model.
de Greef JC; Krom YD; den Hamer B; Snider L; Hiramuki Y; van den Akker RFP; Breslin K; Pakusch M; Salvatori DCF; Slütter B; Tawil R; Blewitt ME; Tapscott SJ; van der Maarel SM
Hum Mol Genet; 2018 Feb; 27(4):716-731. PubMed ID: 29281018
[TBL] [Abstract][Full Text] [Related]
9. The FSHD2 gene SMCHD1 is a modifier of disease severity in families affected by FSHD1.
Sacconi S; Lemmers RJ; Balog J; van der Vliet PJ; Lahaut P; van Nieuwenhuizen MP; Straasheijm KR; Debipersad RD; Vos-Versteeg M; Salviati L; Casarin A; Pegoraro E; Tawil R; Bakker E; Tapscott SJ; Desnuelle C; van der Maarel SM
Am J Hum Genet; 2013 Oct; 93(4):744-51. PubMed ID: 24075187
[TBL] [Abstract][Full Text] [Related]
10. A complex interplay of genetic and epigenetic events leads to abnormal expression of the DUX4 gene in facioscapulohumeral muscular dystrophy.
Gatica LV; Rosa AL
Neuromuscul Disord; 2016 Dec; 26(12):844-852. PubMed ID: 27816329
[TBL] [Abstract][Full Text] [Related]
11. Role of the Chromosome Architectural Factor SMCHD1 in X-Chromosome Inactivation, Gene Regulation, and Disease in Humans.
Wang CY; Brand H; Shaw ND; Talkowski ME; Lee JT
Genetics; 2019 Oct; 213(2):685-703. PubMed ID: 31420322
[TBL] [Abstract][Full Text] [Related]
12. Cis D4Z4 repeat duplications associated with facioscapulohumeral muscular dystrophy type 2.
Lemmers RJLF; van der Vliet PJ; Vreijling JP; Henderson D; van der Stoep N; Voermans N; van Engelen B; Baas F; Sacconi S; Tawil R; van der Maarel SM
Hum Mol Genet; 2018 Oct; 27(20):3488-3497. PubMed ID: 30281091
[TBL] [Abstract][Full Text] [Related]
13. Identification of SMCHD1 domains for nuclear localization, homo-dimerization, and protein cleavage.
Hiramuki Y; Tapscott SJ
Skelet Muscle; 2018 Aug; 8(1):24. PubMed ID: 30071896
[TBL] [Abstract][Full Text] [Related]
14. DNMT3B splicing dysregulation mediated by SMCHD1 loss contributes to DUX4 overexpression and FSHD pathogenesis.
Engal E; Sharma A; Aviel U; Taqatqa N; Juster S; Jaffe-Herman S; Bentata M; Geminder O; Gershon A; Lewis R; Kay G; Hecht M; Epsztejn-Litman S; Gotkine M; Mouly V; Eiges R; Salton M; Drier Y
Sci Adv; 2024 May; 10(22):eadn7732. PubMed ID: 38809976
[TBL] [Abstract][Full Text] [Related]
15. Genetic and epigenetic characteristics of FSHD-associated 4q and 10q D4Z4 that are distinct from non-4q/10q D4Z4 homologs.
Zeng W; Chen YY; Newkirk DA; Wu B; Balog J; Kong X; Ball AR; Zanotti S; Tawil R; Hashimoto N; Mortazavi A; van der Maarel SM; Yokomori K
Hum Mutat; 2014 Aug; 35(8):998-1010. PubMed ID: 24838473
[TBL] [Abstract][Full Text] [Related]
16. Facioscapulohumeral muscular dystrophy type 2: an update on the clinical, genetic, and molecular findings.
Jia FF; Drew AP; Nicholson GA; Corbett A; Kumar KR
Neuromuscul Disord; 2021 Nov; 31(11):1101-1112. PubMed ID: 34711481
[TBL] [Abstract][Full Text] [Related]
17. SMCHD1 is involved in de novo methylation of the DUX4-encoding D4Z4 macrosatellite.
Dion C; Roche S; Laberthonnière C; Broucqsault N; Mariot V; Xue S; Gurzau AD; Nowak A; Gordon CT; Gaillard MC; El-Yazidi C; Thomas M; Schlupp-Robaglia A; Missirian C; Malan V; Ratbi L; Sefiani A; Wollnik B; Binetruy B; Salort Campana E; Attarian S; Bernard R; Nguyen K; Amiel J; Dumonceaux J; Murphy JM; Déjardin J; Blewitt ME; Reversade B; Robin JD; Magdinier F
Nucleic Acids Res; 2019 Apr; 47(6):2822-2839. PubMed ID: 30698748
[TBL] [Abstract][Full Text] [Related]
18. FSHD type 2 and Bosma arhinia microphthalmia syndrome: Two faces of the same mutation.
Mul K; Lemmers RJLF; Kriek M; van der Vliet PJ; van den Boogaard ML; Badrising UA; Graham JM; Lin AE; Brand H; Moore SA; Johnson K; Evangelista T; Töpf A; Straub V; Kapetanovic García S; Sacconi S; Tawil R; Tapscott SJ; Voermans NC; van Engelen BGM; Horlings CGC; Shaw ND; van der Maarel SM
Neurology; 2018 Aug; 91(6):e562-e570. PubMed ID: 29980640
[TBL] [Abstract][Full Text] [Related]
19. FSHD2- and BAMS-associated mutations confer opposing effects on SMCHD1 function.
Gurzau AD; Chen K; Xue S; Dai W; Lucet IS; Ly TTN; Reversade B; Blewitt ME; Murphy JM
J Biol Chem; 2018 Jun; 293(25):9841-9853. PubMed ID: 29748383
[TBL] [Abstract][Full Text] [Related]
20. Deep characterization of a common D4Z4 variant identifies biallelic DUX4 expression as a modifier for disease penetrance in FSHD2.
Lemmers RJ; van der Vliet PJ; Balog J; Goeman JJ; Arindrarto W; Krom YD; Straasheijm KR; Debipersad RD; Özel G; Sowden J; Snider L; Mul K; Sacconi S; van Engelen B; Tapscott SJ; Tawil R; van der Maarel SM
Eur J Hum Genet; 2018 Jan; 26(1):94-106. PubMed ID: 29162933
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
